It is a dopamine-like medication used in the treatment of Parkinson’s disease. It acts on brain cells similar to dopamine. It is administered through subcutaneous injection rather than orally, and its effect starts within a rapid timeframe of 10-20 minutes.
Despite benefiting from oral administration, the presence of end-dose worsening and/or dyskinesias (involuntary movements) necessitates a transition to more advanced treatment methods. Apomorphine helps patients who have been treated with levodopa and/or other dopamine agonists for Parkinson’s disease to transition from an “off” (closed, immobile) to an “on” (open, relaxed) state.
Apomorphine, which is produced for such special circumstances, has two types of applications. The first is repeated subcutaneous injection throughout the day. It helps the patient, who is stuck in the “off” state due to the ineffectiveness of the medication being used, to regain movement within a short period of 5-10 minutes with the application of an Apomorphine injection. For patients with severe condition of Parkinson’s disease, continuous administration of Apomorphine through a portable pump under the skin helps reduce the time spent in immobility and alleviate symptoms. It enables continuous administration of the medication throughout the day.